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S_inaary Radiolabelled meta-iodobenzylguanidine (mIBG) currently provides one of the most promising
options for targeted radiotherapy of neuroblastoma. No means currently exists for prediction of mIBG uptake
in tumour cells of individual patients other than semiquantitative inferences from diagnostic scanning which
depend on the continued existence of a macroscopic tumour mass. A biological rapid assay which could be
applied at initial biopsy would be invaluable in selecting patients for therapeutic strategies which incorporate
radiolabeled mIBG. We have assesed the expression of the noradrenahne transporter gene in six human
neuroblastoma cell lines and in three non-neural crest-derived cell lines using reverse transcription followed by
the polymerase chain reaction. Transcription of this gene was observed in five out of six neuroblastoma cell
lines but in none of the control cells. A highly significant correlation was established (P<0.O1) between gene
expression and active cellular accumulation of mIBG. It is suggested that semiquantitative evaluation of
noradrenaline transporter gene transcripts may be predictive of mIBG uptake by tumours in vivo.
Meta-iodobenzylguanidine (mIBG) is a derivative of the
adrenergic neurone-blocking drugs bretylium and guanethidine
(Wieland et al., 1980). This compound is selectively concen-
trated in neuroadrenergic tissue by an ATPase-dependent
process known as Uptake-i, which is the mechanism respon-
sible for the active re-uptake of noradrenaline by presynaptic
sympathetic nerve cells (Jaques et al., 1987). Since tumours
derived from the neural crest can accumulate and store
mIBG, radioiodinated ('"'I or '23I) forms of the drug are
employed for the scintigraphic visualisation of neuroblastoma
(Feine et al., 1987) and phaeochromocytoma (Shapiro et al.,
1985).
In recent years, much interest has focused on targeted
radiotherapy for neuroblastoma by means of high specific
activity preparations of '31I-mIBG. This form of treatment
has produced some encouraging results (Voute et al., 1991;
Lashford et al., 1992). Alternative strategies for the optimal
therapeutic application of this radiopharmaceutical are cur-
rently being explored in treatment centres worldwide.
In order to identify those patients for whom '31I-mIBG
therapy will be appropriate, and to estimate dosimetry and
response to this form of treatment, a pretherapy '31I-mIBG
or '"I-mIBG tracer study is usually carried out. However,
this procedure is only useful in patients at diagnosis or with
residual macroscopic tumour after initial treatment. Using
radioactive reference sources placed near the site of malig-
nancy, the tumour dose can be calculated (assuming uniform
distribution of radionucide) from gamma-camera imaging
performed over several days (Beierwaltes, 1987). However,
scintigraphic estimates of mIBG acquisition by neuroblas-
toma have been shown to correlate imperfectly with the
actual radiopharmaceutical upake, measured by radioactivity
counting of tumour biopsy specimens (Moyes et al.,
1989).
It is not uncommon for whole-body scintigraphy following
'311-mIBG therapy to demonstrate tumour uptake in areas
which appeared normal on previous diagnostic mIBG scans
both in patients whose diagnostic scans showed mlBG
positivity at other sites and in patients with entirely negative
diagnostic mIBG scans (Gaze et al., 1994). It is possible that
these discrepancies are due to dissimilarities in the pharma-
cokinetics of diagnostic and therapeutic preparations of 131-
mIBG because of differences in the total amount of drug
administered (Fielding et al., 1992). As a result of the
unreliability of diagnostic scintigraphy as a predictor of the
uptake of therapeutic mIBG, practice with regard to mIBG
imaging varies from centre to centre. While some clinicians
regard evidence of mIBG uptake on a preliminary scan as a
prerequisite for mlBG therapy, others are prepared to treat
patients who either have not been scanned or whose scans
were negative (Gaze et al., 1994).
The recent description of the base sequence of the nor-
adrenaline transporter gene (Pacholczyk et al., 1991) has
facilitated the sensitive detection of its transcripts by reverse
transcription-polymerase chain reaction (RT-PCR)
(Monaldo et al., 1991). To look for a cost-effective alterna-
tive to time-consuming mIBG scintigraphic procedures of
dubious precision and a procedure which should be ap-
plicable to all patients irrespective of disease status, we have
evaluated the potential of RT-PCR to predict mIBG uptake
using a panel of neuroblastoma cell lines of human
origin.
Materiak and methods
Cell culture
The following human neuroblastoma cell lines were used:
SK-N-SH (Biedler et al., 1973), SK-N-BE(2c) (Biedler et al.,
1978), NB-100 (Schlesinger et al., 1976), IMR-32 (Tumi-
lowicz et al., 1970), NBI-G (Carachi et al., 1987) and NB3-
G, a previously unreported cell line which was established
from the primary abdominal neuroblastoma tumour of a
34-month-old female patient with stage 4 disease who had
attended for treatment at the Royal Hospital for Sick Child-
ren, Glasgow. Scintigraphy with 131I-mIBG in this patient
had shown only poor uptake in her primary tumour. In
addition, three non-neural crest-derived control cell lines
were evaluated. These were breast carcinoma MCF-7 (Soule
et al., 1973), cervical carcinoma HeLa (Scherer et al., 1953)
and ovarian carcinoma A2780, a variant of the line
NIH:OVCAR-3 (Hamilton et al., 1983).
AU ceUs were cultured in Eagle's minimal essential medium
supplemented with 10% fetal calf serum, 2 mM glutamine,
penicillin-streptomycin (100 IU ml-') and amphotericin B
(2.5 ;Lgml-'). All media and supplements were purchased
from Gibco (Paisley, UK).
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Cells were seeded into six-well plates (Nunc, Denmark) at
an initial density of 5 x I05 per well. They were cultured as
monolayers for 2-4 days at 37C in 5% carbon dioxide.
'31I-mIBG of specific activity greater than 30 TBq mmol'
(no carrier added, n.c.a.) was synthesised by iododesilylation
of meta-trimethylsilylbenzylguanidine as previously described
(Vaidyanathan & Zalutsky, 1993). Desmethylimipramine was
obtained from Sigma (Poole. Dorset, UK).
mIBG uptake
The ability of cell lines to take up mIBG was assessed as
previously described (Mairs et al., 1991). Briefly, the cell
monolayers were incubated with 7 kBq of n.c.a. "3'I-mIBG,
so that the drug concentration was less than 100 pM. After
2 h at 37°C, the cells were washed twice with cold phosphate-
buffered saline and radioactivity was extracted with two
0.5 ml aliquots of 10% (w/v) trichloroacetic acid. The activity
of the combined extracts was measured in a Cobra II
automatic gamma counter (Canberra Packard, Berkshire,
UK).
Desmethylimipramine is a tricyclic antidepressant which
inhibits the re-uptake of neurotransmitters by adrenergic
neurones. To determine the percentage contribution to cel-
lular accumulation of the radiopharmaceutical by the active,
uptake-l process. cells were preincubated for 30 min with
1.5 M desmethylimipramine in the absence of mIBG. The
medium was then replaced by one containing both drugs
and, after 2 h, the uptake of radioactivity was measured as
described above.
RT-PCRfor analysis ofnoradrenaline transporter mRNA
Amplimer sequences were designed (Montaldo et al., 1992)
from the published nucleotide base sequence for
noradrenaline transporter cDNA (Pacholczyk et al., 1991).
The sense noradrenaline transporter primer (5'-CTGGTG-
GTGAAGGAGCGCAACGGC-3') corresponds to the nor-
adrenaline transporter cDNA sequence 100-123. The
antisense noradrenaline transporter primer (5'ATGT-
CATGAATCCCGCTGCTCTCG-3') represents the antisense
strand of the noradrenaline transporter cDNA sequence
666-689. These generated a 590bp PCR product with two
internal HaeIII sites and two AluI sites. Human 28S
ribosomal RNA (Gonzalez et al., 1985), chosen as internal
standard, was also reverse transcribed and amplified. A
346bp region of the cDNA derived from 28S rRNA was
flanked by the oligomers 5'-GAAAGATGGTGAACTATG-
CC-3' (sense), corresponding to 28S rDNA bases
1,501-1,520 and 5'-TTACCAAAAGTGGCCCACTA-3'
(antisense), corresponding to bases 1,827-1,846. This 346 bp
sequence contained two HaeIII and two EcoRII sites. All
amplimers were obtained from Oswel DNA Service (Edin-
burgh, UK).
From approximately 5 x 106 cells in exponential growth
phase, total RNA was extracted by RNAzol (Biogenesis,
Bournemouth, UK), purified according to the manufacturer's
protocol and quantified spectrophotometrically after dissolu-
tion in diethylpyrocarbonate-treated water. One microgram
of total RNA from each of the cell lines was converted into
first-strand cDNA using a Superscript Preamplification
System (Gibco, Paisley, UK). The manufacturer's protocol
was followed except for the following modifications:
10 x synthesis buffer consisted of 100 mM Tris-HCI
(pH 8.3), 500mM potassium chloride and 0.01% (w/v)
gelatin; 30 nmol of magnesium chloride was added
separately. The cDNA synthesis was carried out at 45C.
Co-amplification of target and reference sequences was
achieved by PCR using 20 pmol of each target sequence
primer and 30pmol of each reference sequence primer to
which 150 nmol of magnesium chloride was added.
Each sample was amplified by 35 cycles of PCR using an
Omnigene thermal reactor (Hybaid, Middlesex, UK). Each
cycle consisted of a 1 min denaturation at 94°C, followed by
1 min of annealing at 65°C and 1 min of extension at 72'C,
according to the method of Montaldo et al. (1992). Aliquots
of 20 .tl of the PCR products were electrophoresed in 2%
(w/v) agarose and the gels were stained with ethidium
bromide. As negative controls, 1 ;Lg RNA aliquots of each
sample were treated as above but without the inclusion of
reverse transcnptase. The relative intensities of the bands
were quantified using photographic negatives of the ethidium
bromide-stained gels. Densitometry was performed on a
Molecular Dynamics computing densitometer (Sevenoaks,
Kent, UK) and images were analysed using the Quantity 1
programme from Pharmacia (Herts, UK).
Results were expressed as ratios:
Intensity of target sequence sample
Intensity of reference sequence sample
To determine the effect of the amount of total RNA upon
the quantity of amplified target sequence, a range of amounts
of total RNA, isolated from the cell line SK-N-BE(2c), were
subjected to RT-PCR and the products were electro-
phoresed and densitometrically evaluated.
To confirm that the PCR products were homologous to
noradrenaline transporter cDNA and 28S rDNA, specifically
amplified products were digested with HaeIIl, EcoRII and
AluI restriction endonucleases.
In order to assess the reproducibility of the methology, six
separate RT-PCRs were performed on the RNA isolates
from those cell lines which generated a target signal: SK-N-
SH, SK-N-BE(2c), IMR-32 and NBI-G.
Results
mIBG uptake
Active accumulation of mIBG in cells was determined by
comparing the uptake of radioactivity in the presence and
absence of desmethylimipramine - a specific inhibitor of
noradrenaline receptor-mediated monoamine transport. At
concentrations of mIBG lower than 0.1 iLM, preferential
accumulation of the drug by Uptake-l is apparent in those
cells which possess the specific transport mechanism (Smets
et al., 1989; Lashford et al., 1991; Mairs et al., 1991; Mon-
taldo et al., 1991), whereas at higher concentrations of the
radiopharmaceutical there is an increasng contribution to
total drug uptake by non-specific transport processes. In the
present study carrier-free '3'I-mIBG was used at extremely
low concentrations (less than 100 pM) in the incubation
medium in order to enhance the detectability of specific,
desmethylimipramine-inhibitable transport. Five out of six
neuroblastoma cell lines but none of the non-neural crest-
derived cell lines demonstrated active uptake of the radio-
pharmaceutical (Table I). It has previously been reported
that IMR-32 neuroblastoma cells are capable of the concen-
tration of mIBG only by energy-independent processes (Buck
et al., 1985). Therefore, it is possible that the modest contri-
bution to drug accumulation by Uptake-l observed in IMR-
32 cells for the first time in the present study may have been
due to the extremely low experimental concentration of
radiopharmaceutical.
The meagre level of active uptake noted for NB3-G cells
was in accord with the poor concentration of '3'I-mIBG
achieved in tumour sites of the patient from whom this cell
line was derived.
Evaluation ofnoradrenaline transporter mRNA by RT-PCR
The identity of RT-PCR-amplified products was confirmed
by restriction endonuclease digestion. cDNA from SK-N-
BE(2c) cells was amplified in separate reactions using primers
specific for target or reference sequences. Thereafter the PCR
target product was digested with AluI and HaeIII and the
reference product was digested with EcoRII and HaeIII.
These reactions yielded fragments of the predicted sizes
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Table I mIBG uptake by neuroblastoma and non-neuronal cell
lines compared with noradrenaline transporter gene expression
Desmethvlimipramine- Noradrenaline transporter
inhibitable mIBG mRNA productionb
uptake' (cpim. x 103 (target-to-reference
Cell line per lo-6 cells) intensiti ratio)
SK-N-BE (2c) 114± 8 1.94 0.06
SK-N-SH 107 10 1.38 0.09
NBI-G 26± 4 0.53±0.01
IMR-32 12± 2 0.38±0.04
NB3-G I Trace'
NB-100 -
HeLa
MCF-7 _
A2780 -
'Uptake measurements were made after 2 h incubation in the
presence of 7 kBq n.c.a. '3'I-mIBG with or without 1.5gM
desmethylimipramine. Accumulated radioactivity is expressed as
mean ± s.d. of three experiments in triplicate. 'Six separate
RT-PCRs were performed on RNA isolates from those cell lines
which generated a ratio value greater than zero. Results are reported
as mean ± s.d. of target-to-reference intensity ratios which were
obtained by densitometric analysis of the photographic negatives of
ethidium bromide-stained gels. cln this sample, the signal from the
amplified target sequence. although visible, was too weak to be
detected densitometrically.
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Fugwe I Specificity of RT-PCR. Separate RT-PCRs were per-
formed on SK-N-BE(2c) cell RNA to generate amplified products
from noradrenailne transporter mRNA (target) and 28S rRNA
(reference). These were then subjected to restriction endonuclease
digestion. Lanes 1 and 6, 123 bp ladder-, lane 2, target sequence,
HaeIII; lane 3, target sequence/AluI; lane 4, undigested target
sequence; lane 5, control reaction for target sequence performed
using all of the reagents except RT; lane 7, reference sequence/
EcoRII; lane 8, reference sequence/HaeIII; lane 9, undigested
reference sequence; lane 10, control reaction for reference
sequence, performed using all of the reagents except RT. The
sizes of the amplified transcripts and their restriction fragments
are shown.
the omission of reverse transcriptase resulted in the absence
of PCR-amplified products (Figure 1), demonstrating that
both the target and reference PCR products were derived
from cDNA rather than genomic DNA templates.
To determine the optimal quantity of total RNA and the
sensitivity of the method, varying amounts of RNA isolated
from SK-N-BE(2c) cells were subjected to RT-PCR, em-
ploying noradrenaline transporter-specific amplimers. The
limit of detection was less than 50 ng of total RNA. The
intensity of the product band increased from 50 ng to I gg of
RNA. Amounts of RNA greater than 1 jg yielded no inc-
rease in product (Figure 2).
RT-PCR revealed transcription of the noradrenaline
transporter gene in five out of six neuroblastoma cell lines.
The RT-PCR signal from the neuroblastoma cell line NB3-
G was just discernible by visual inspection, but was not
sufficiently intense to allow detection by densitometric scann-
ing. All three non-neuronal cell lines were negative for target
Fge 2 Determination of optimal RNA content. RT-PCRs
for specific amplification of noradrenaline transporter target
sequence were performed using a range of amounts of RNA
isolated from SK-N-BE(2c) cells.
Fugwe 3 RT-PCR evaluation of noradrenaline transporter gene
expression by neuroblastoma cell lines using co-amplification of
target and reference sequences. One-fifth of the PCR product
(20 1d) was loaded per lane. Lane 1, 123 bp ladder, lane 2,
NB-100; lane 3, SK-N-SH; lane 4, NBI-G; lane 5, NB3-G; lane 6,
SK-N-BE(2c); lane 7, IMR-32; lane 8, HeLa; lane 9, A2780; lane
10, MCF-7. The upper band (590 bp) corresponds to a region of
noradrenaline transporter cDNA. The lower band (346 bp)
represents the co-amplified internal reference sequence of the
constitutively expressed 28S rRNA.
sequence production (Figure 3). The simultaneous amplifica-
tion of constitutively expressed 28S rRNA permitted a com-
parison of the level of expression of the noradrenaline trans-
porter gene between different cell lines (Figure 3). This cor-
related significantly (P<0.01) with the capacity for active
uptake of mIBG (Figure 4).
The precision of this RT-PCR system was determined by
performing six replicate syntheses of target and reference
sequences on RNA isolates from the four cell lines (SK-N-
BE(2c), SK-N-SH, NBI-G and IMR-32) which produced
substantial amounts of amplified target fragments. The coef-
ficients of variation of the electrophoretic band intensity
ratios were 10.5% (IMR-32), 13.2% (NBI-G), 6.5% (SK-N-
SH) and 3.1% (SK-N-BE(2c) (Figure 5).
Eiscussion
An increased understanding of the genetic abnormalities
associated with cancer cells has resulted in the development
of a range of novel diagnostic techniques. Among these,
PCR-based methodologies are particularly attractive because
they allow the evaluation of characteristics of malignant
tissue when only small samples are available for analysis.
PCR has great potential not only for use in the diagnosis of
many types of cancer, but also in staging and monitoring of
treatment response. Applications of PCR to the planning of
neuroblastoma therapy have been reported: the detection of
circulating metastases by tyrosine hydroxylase (Smith et al.,
1992) or neuroendocrine protein-specific RT-PCR (Mattano
et al., 1992) and the assessment of the prognostic indicator,
N-myc gene amplification, by differential PCR (Huddart &
Mann, 1993). Another role for the PCR in the assessment of
neuroblastoma patients was suggested by the observation of
interferon-y-enhanced uptake of mIBG by cultured neuro-
blastoma cells as a result of increased expression of the
noradrenaline transporter gene (Montaldo et al., 1992).
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Fugwe 4 The produclton of noradrenaline transporter mRNA as
a function of specific uptake of "'I-mIBG by neuroblastoma
celis. For the determination of radiopharmaceutical uptake, cells
were incubated for 2 h with 7 kBq of ELca. '3'I-mIBG. Specific
uptake was obtained by subtracting accumulated c.p.m. in the
presence of 1.5 pM desnethyhmipramine from accumulated
c.p.m. in the absence of this inhibitor. Points represent the means
and standard deviations of three experiments in tripicate.
Estimation of expression of the noradrenaline tasporter gene
was performed six times on the cells lnes SK-N-BE(2c), SK-N-
SH, NBI-G and IMR-32. Experimental points are the means and
standard deviations of target-to-reference signal intensty ratios.
The experimental point at the ongin of both axes represents
NB-100. The point at the origin of the ordinate with a vahle of 1
on the abscissa represents NB3-G.
a
c
FIwe 5 Assessment of precision of noradrenaline transporter
mRNA evaluation. a, SK-N-BE(2c). b, SK-N-SH. c, NB1-G. d,
IMR-32. Six replicate determinations of target-to-reference
sequence intensity ratio were performed. The means and standard
deviations of the ratios are given in Table I.
We undertook a comparative assessment of transcripts of
this gene in six neuroblastoma cell lines. A highly significant
correlation (P<0.01) with cellular accumulation of mIBG
was established. The RT-PCR procedure was specific (target
mRNA sequences were absent in control cells and the PCR
product and its restiction endonuclease-denved fragments
were of the predited sizes), reproducible (coefficient of varia-
tion <13.2%) and sensitive (detection limit <50ng of total
RNA). This suggests that semiquantitative evaluation of
noradrenaine transporter gene transcripts may be predictive
of mlBG uptake in vivo. However, results obtained under
experimental conditions with homogeneous populations of
cultured cells may not give an accurate reflection of the
performance of the technique under clinical conditions. In
order to assess the applicability of noradrenaline transporter
RT-PCR data in a clinical setting, controlled trials will have
to be undertaken. Ideally these should involve comparisons
of estimates of mIBG uptake from gamma-camera images
with predictions of radiopharmaceutical accumulation based
upon mRNA assays of punch biopsy specimens. Where
available, tumours resected after 13'I-mIBG adm ation
could be assessed for radioactivity content to give an
accurate determination of radiopharmaceutical uptake
(Moyes et al., 1989). Meantime, useful information may be
acquired by comparison of RT-PCR assay with mIBG scan-
ning after diagnostic or therapeutic doses of '3'I-mIBG.
At presentation, most patients with neuroblastoma under-
go an open or needle biopsy for pathological confirmation of
the diagnosis, prior to induction chemotherapy. Despite the
desirability of knowing whether or not the tumour has the
capacity to take up mIBG, and although mIBG scanning is
now accepted by most groups as a necessary investigation in
the diagnostic work-up, not all patents have an mIBG scan
at presentation. Use of nning to evaluate mlBG uptake
per unit mass requires concomitant estimation of tumour size
(e.g. by CTsanning) and may be very imprecise. Moreover,
following apparently successful primary chemotherapy, there
may be no macroscopic residual tumour for imaging by
131I-mIBG or '23I-mlBG scintigraphy, yet there may be
residual subcinical foci or disease. Although an unproven
method, there is an emerging interest in the use of mIBG
therapy as part of high-dose consolidation schedules or
megatherapy (Corbett et al., 1992; Gaze et al., 1994). If an
initial scan was not performed, it will not be possible to
know the mIBG status of the tumour, and therefore the
therapeutic benefit of '1I-mIBG therapy in consolidation
schedules is unpredictable. In these circumstances, RT-PCR
evaluation of RNA obtained from biopsy specimens could be
an alternative means of estimating tumour capacity for
mIBG uptake.
A problem associated with the analysis of tumour biopsy
material is heterogeneity of drug uptake due to phenotypic
diversity, hypoxia or normal tissue contamination. In some
cases, prediction of gross mIBG uptake per unit tumour mass
is what is required, i.e. when radiolabelled mlBG is used as
part of the primary treatment. In other situations, it would
be desirable to infer the mIBG uptake of viable tumour cells,
i.e. when radiolabelled mIBG is used as part ofconsolidation
treatment for residual disease following removal of bulk
tumour. A noradrenaline transporter mRNA evaluation em-
ploying 28S rRNA as reference sequence would only give an
estimate of mIBG uptake capacity relative to the total viable
(tumour and non-tumour) cellular content of a sample. To
predict tumour cell concentration of mIBG more accurately,
it may be necessary to use alternative internal standards with
specificity for neuroblastoma cells. Possibilities include the
transcript of the tyrosine hydroxylase gene (Smith et al.,
1992) which is expressed only in catecholamine-synthesising
cells, or mRNA specific for neural crest cell proteins such as
PGP 9.5 (Mattano et al., 1992). As an alternative, RT-PCR
could be performed on malignant cells obtained from the
bone marrow, which may avoid the sampling error inherent
in needle biopsies of heterogeneous tumours.
In conclusion, we have found the RT-PCR assay to be
specific, reproducible and sufficiently sensitive to allow the
analysis of about one thousand cells. In addition, the level of
expression of the noradrenaline transporter gene was consist-
ent with the capacity of neuroblastoma cells to actively
accumulate mIBG. This technique may provide a more reli-
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able criterion for patient selection for mIBG therapy than
current scintigraphic methods, which are in any case only
applicable when bulk tumour is present.
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